background
earli
detect
acut
respiratori
distress
syndrom
ard
potenti
improveth
prognosi
critic
ill
patient
admit
intens
care
unit
icu
howev
reliabl
biomark
current
avail
accur
earli
detect
ard
patient
predispos
condit
object
studi
examin
risk
factor
biomark
ard
develop
mortal
two
prospect
cohort
studi
method
examin
clinic
risk
factor
ard
cohort
patient
beij
china
admit
icu
high
risk
ard
identifi
biomark
replic
second
cohort
patient
boston
usa
result
patient
recruit
particip
hospit
beij
develop
ard
multivari
adjust
sepsi
odd
ratio
ci
pulmonari
injuri
ci
thrombocytopenia
defin
platelet
count
ml
ci
significantli
associ
increas
risk
develop
ard
thrombocytopenia
also
associ
increas
mortal
patient
develop
ard
adjust
hazard
ratio
ahr
ci
develop
ard
ahr
ci
presenc
thrombocytopenia
ard
substanti
increas
sensit
analys
show
platelet
count
mlin
combin
ard
provid
highest
prognost
valu
mortal
associ
replic
cohort
us
patient
conclus
studi
icu
patient
china
us
show
thrombocytopenia
associ
increas
risk
ard
platelet
count
combin
ard
high
predict
valu
patient
mortal
acut
respiratori
distress
syndrom
ard
sever
form
acut
lung
injuri
ali
caus
sever
direct
indirect
insult
lung
life
threaten
often
lethal
ard
usual
requir
mechan
ventil
admiss
intens
care
unit
icu
ard
major
caus
icu
morbid
mortal
worldwid
emerg
viral
diseas
sever
acut
respiratori
syndrom
sar
coronaviru
avianorigin
influenza
viru
swineorigin
influenza
viru
possess
potenti
pandem
spread
also
caus
ard
factor
highlight
need
addit
research
improv
understand
pathogenesi
ard
ultim
goal
develop
specif
treatment
ard
associ
sever
clinic
disord
includ
direct
pulmonari
injuri
pneumonia
aspir
extrapulmonari
injuri
sepsi
trauma
multipl
transfus
although
low
tidal
volum
ventil
neuromuscular
blocker
prone
posit
ventil
advanc
treatment
current
reliabl
predict
marker
earli
detect
ard
predispos
individu
nonetheless
mani
effort
mount
identifi
biolog
marker
biomark
ard
critic
ill
patient
includ
studi
pulmonari
edema
fluid
blood
urin
recent
advanc
pathophysiolog
mechan
underli
ard
identifi
sever
clinic
biomark
assess
diseas
sever
outcom
includ
specif
cytokin
receptor
solubl
tumor
factor
receptor
ii
product
epitheli
endotheli
injuri
receptor
advanc
glycat
endproduct
rage
surfact
protein
von
willebrand
factor
antigen
marker
alter
coagul
protein
c
plasminogen
activ
howev
individu
biomark
strongli
associ
outcom
thu
provid
suffici
discrimin
power
either
diagnosi
prognosi
biomark
discoveri
valid
requir
patient
sampl
must
combin
comprehens
clinic
data
collect
properli
design
trial
differ
popul
given
acut
onset
rapid
clinic
progress
ard
prospect
enrol
cohort
studi
multicent
icu
suitabl
complet
unbias
ardsali
research
use
protocol
modifi
molecular
epidemiolog
ard
studi
establish
boston
boston
cohort
establish
multicent
ard
cohort
beij
china
beij
cohort
overarch
object
establish
prospect
cohort
valid
relev
biomark
ard
well
genet
polymorph
discov
previou
usa
studi
chines
popul
discov
new
biomark
ard
comprehens
sampl
protocol
report
present
initi
result
clinic
factor
associ
ard
develop
mortal
individu
risk
ard
associ
clinic
factor
replicatedin
boston
cohort
studi
approv
institut
review
board
irb
peke
univers
third
hospit
beij
friendship
hospit
chinajapan
friendship
hospit
beij
chaoyang
hospit
harvard
school
public
health
written
inform
consent
obtain
subject
appropriateproxi
patient
four
medic
surgic
icu
within
four
tertiari
hospit
particip
studi
hospit
cover
metropolitan
area
beij
china
includ
peke
univers
third
hospit
northwest
bed
beij
friendship
hospit
south
bed
beij
chaoyang
hospit
east
bed
chinajapan
friendship
hospit
northeast
bed
intern
collabor
use
modifi
studi
protocol
recruit
previous
describ
briefli
screen
icu
admiss
elig
subject
defin
critic
ill
patient
least
one
predispos
condit
ard
sepsi
septic
shock
trauma
pneumonia
aspir
massiv
transfus
pack
red
blood
cell
prbc
defin
prbc
unit
hour
prior
admiss
sever
pancreat
avoid
interfer
biomark
research
certain
clinic
condit
exclus
criteria
age
year
histori
chronic
lung
diseas
interstiti
pulmonari
fibrosi
bronchiol
histori
pneumonectomi
treatment
immunomodul
therapi
corticosteroid
granulocyt
coloni
stimul
factor
cyclophosphamid
cyclosporin
interferon
tnfa
antagonist
presenc
immunodefici
condit
hiv
infect
leukemia
neutropenia
absolut
neutrophil
count
histori
solid
bone
marrow
transplant
autolog
bone
marrow
transplant
direct
withhold
intub
sepsi
septic
shock
defin
american
colleg
chest
physicianssocieti
critic
care
medicin
accpsccm
consensu
confer
enrol
subject
follow
daili
develop
ard
defin
americaneuropean
consensu
committe
aecc
follow
evid
hypoxemia
pao
fio
mm
hg
b
evid
bilater
infiltr
chest
radiograph
c
absenc
left
atrial
hypertens
pulmonari
arteri
occlus
pressur
mm
hg
congest
heart
failur
control
identifi
atrisk
patient
meet
criteria
ard
icu
stay
prior
histori
ard
infiltr
chest
radiograph
defin
opac
could
explain
complet
pleural
effus
mass
bodi
habitu
collaps
upper
zone
redistribut
pulmonari
vascular
congest
consid
infiltr
two
pulmonari
critic
care
physician
interpret
daili
chest
radiograph
disagr
went
third
intensivist
arbitr
physician
underw
consensu
train
session
radiolog
criteria
ard
blind
clinic
statu
patient
collect
clinic
data
chart
review
includ
demograph
inform
age
gender
race
height
weight
medic
histori
ard
diabet
tobacco
alcohol
abus
liver
diseas
baselin
clinic
inform
worst
vital
sign
laboratori
test
result
first
hour
icu
admiss
collect
calcul
acut
physiolog
chronic
health
evalu
apach
ii
score
sever
ill
also
collect
ventilatori
paramet
includ
requir
mode
mechan
ventil
pao
fio
ratio
posit
endexpiratori
pressur
tidal
volum
peak
plateau
pressur
enrol
patient
follow
one
follow
situat
occur
hospit
discharg
death
day
studi
entri
start
late
base
find
ard
network
trial
chines
icu
univers
adopt
lower
tidal
volum
mechan
ventil
baselin
characterist
compar
group
fisher
exact
test
chisquar
test
dichotom
categor
variabl
student
test
mannwhitney
test
continu
variabl
risk
analysi
ard
develop
initi
use
logist
regress
model
backward
stepwis
elimin
algorithm
select
clinic
risk
predictor
univari
analys
final
logist
regress
model
also
includ
predictor
backward
elimin
mortal
analysi
use
logrank
test
univari
measur
associ
employ
cox
proport
hazard
model
investig
clinic
variabl
effect
clinic
outcom
use
timedepend
receiv
oper
characterist
roc
method
determin
best
cutoff
valu
thrombocytopenia
predict
prognosi
critic
ill
patient
explor
areaunderthecurv
auc
valu
mortal
select
maxim
sumof
sensit
specif
analys
perform
sa
statist
softwar
packag
version
sa
inc
cari
nc
consid
statist
signific
juli
april
recruit
patient
least
one
predispos
condit
ard
particip
hospit
beij
china
major
patient
male
n
mean
age
year
median
interquartil
rang
year
tabl
median
apach
ii
score
interquartil
rang
median
length
time
icu
day
interquartil
rang
day
mechan
ventil
use
patient
median
length
six
day
interquartil
rang
day
thirtynin
patient
diabet
one
patient
chronic
kidney
diseas
hospit
patient
develop
ard
among
identifi
ard
patient
diagnos
within
first
hour
icu
admiss
respect
signific
differ
age
gender
smoke
statu
initi
apach
ii
score
ard
patient
atrisk
nonard
patient
tabl
addit
major
physiolog
variabl
first
hour
icu
admiss
compar
except
patient
develop
ard
higher
respiratori
rate
p
although
signific
ard
patient
icu
longer
ard
median
day
nonard
median
day
p
mechan
ventil
longer
ard
median
day
nonard
median
day
p
nonard
patient
low
tidal
volum
mlkg
use
treat
patient
mechan
ventil
although
patient
specif
data
avail
protocol
low
tidal
volum
ventil
standard
studi
icu
among
predispos
condit
ard
enrol
patient
sepsi
andor
septic
shock
n
associ
develop
ardsrespiratori
rate
breathsmin
aspir
risk
ard
also
evalu
model
select
elimin
model
select
signific
apach
ii
score
remov
age
gender
compon
age
gender
forc
covariatesbut
signific
logist
regress
analys
known
factor
relat
ard
includ
septic
shock
diabet
alcohol
use
also
test
either
forc
covari
individu
combin
model
chang
signific
associ
sepsi
direct
pulmonari
injuri
thrombocytopenia
develop
ard
data
shown
drink
habit
china
differ
us
difficult
develop
compar
criterion
alcohol
abus
includ
alcohol
abus
risk
factor
analysi
conduct
stratifi
analysi
found
thrombocytopenia
significantli
associ
ard
beij
cohort
univari
analysi
p
boston
cohort
univari
analysi
tabl
ard
nonard
patient
recruit
massachusett
gener
hospit
boston
usa
subgroup
patient
septic
shock
nonsept
shock
subgroup
p
p
respect
patient
alreadi
develop
ard
icu
admiss
subgroup
caseswa
usual
mix
patient
diagnos
ard
first
hour
icu
admiss
togeth
account
total
ard
beij
cohort
boston
cohort
identifi
case
sinc
thrombocytopenia
defin
lowest
platelet
count
first
hour
icu
admiss
cohort
patient
develop
thrombocytopenia
onset
ard
difficult
distinguish
within
subgroup
ard
could
interfer
find
thrombocytopenia
associ
develop
ard
perform
nest
analysi
clean
subgroup
patient
remov
ard
patient
diagnos
first
hour
icu
admiss
found
thrombocytopenia
still
significantli
associ
ard
risk
ci
p
small
sampl
size
beij
cohort
conduct
sensit
test
boston
cohort
ard
case
nonard
patient
remov
ard
patient
mortal
rate
patient
develop
ard
increas
mortal
risk
tabl
among
predispos
condit
ard
septic
shock
associ
increas
mortal
p
pancreat
associ
decreas
mortal
p
ard
patient
tabl
contrast
pneumonia
p
extern
pulmonari
injuri
p
higher
mortal
rate
nonard
patient
univari
examin
demograph
characterist
physiolog
variabl
first
hour
icu
admiss
reveal
higher
apach
ii
score
older
age
associ
increas
mortal
ard
nonard
patient
tabl
thrombocytopenia
significantli
associ
mortalityof
ard
p
nonard
p
patient
contrast
high
serum
creatinin
level
mgl
associ
higher
mortal
nonard
p
ard
p
patient
statist
signific
differ
survivor
nonsurvivor
gender
histori
diabet
tobacco
alcohol
use
multivari
analysi
apach
ii
score
consist
associ
increas
mortal
ard
nonard
patient
tabl
thrombocytopenia
mortal
covari
ard
patient
nonard
patient
tabl
replac
coagul
point
sequenti
organ
failur
assess
score
sofa
thrombocytopenia
remain
associ
higher
mortal
ard
adjust
hazard
ratio
ahr
ci
p
patient
ahr
ci
p
nonard
patient
ahr
ci
p
replic
find
analyz
data
boston
cohort
although
univari
analys
identifi
physiolog
variabl
first
hour
icu
admiss
ardspredispos
condit
significantli
associ
mortal
tabl
multivari
analys
identifi
apach
ii
score
thrombocytopenia
major
risk
factor
mortal
ard
nonard
patient
tabl
also
found
similar
result
thrombocytopenia
replac
coagul
point
sofa
score
data
shown
investig
interact
thrombocytopenia
ard
mortal
patient
creat
combin
covari
boston
beij
cohort
univari
figur
multivari
figur
analys
combin
thrombocytopenia
ard
consist
higher
patient
mortal
take
advantag
size
boston
cohort
conduct
sensit
analysi
determin
optim
platelet
count
prognosiswith
adjustmentsfor
age
gender
apach
ii
score
sepsi
platelet
count
mlhad
maxim
roc
valu
auc
sensit
specif
p
sensit
analysi
confirm
platelet
count
ml
consid
seri
step
ml
cut
prospect
multicent
cohort
establish
use
modifi
protocol
origin
implement
boston
cohort
among
atrisk
icu
patient
develop
ard
icu
admiss
major
patient
develop
ard
within
first
hour
admiss
observ
consist
previou
report
mostlycaucasian
boston
cohort
moreov
profil
baselin
physiolog
variabl
major
clinic
risk
factor
ard
atrisk
nonard
patient
similar
previou
report
chines
andamerican
icusfurthermor
observ
high
baselin
respiratori
rate
breathsmin
associ
ard
case
consist
withth
find
sever
previou
studi
cohort
addit
sepsi
direct
pulmonari
injuri
thrombocytopenia
associ
develop
ardsenhanc
platelet
activ
result
platelet
deposit
within
damag
pulmonari
microvasculatur
support
sever
clinic
preclin
studi
ali
thrombocytopenia
report
key
featur
sar
boston
cohort
thrombocytopenia
name
hematolog
failur
also
identifi
risk
factor
ard
multivari
analysi
anoth
cohort
ali
rochest
minnesota
mayo
clinic
howev
research
observ
signific
differ
platelet
count
ali
nonali
patient
septic
shock
sinc
rochest
cohort
focus
subgroup
icu
patient
septic
shock
stratifi
analysi
reveal
thrombocytopenia
significantli
associ
ard
beij
cohort
boston
cohort
subgroup
patient
septic
shock
nonsept
shock
subgroup
differ
result
might
explain
beij
cohort
boston
cohort
focus
ard
sever
form
ali
major
find
studi
associ
ofthrombocytopenia
increas
ard
mortal
extens
evid
demonstr
platelet
count
function
independ
associ
increas
icu
morbid
mortal
although
thrombocytopenia
wellestablish
prognost
marker
mortal
patient
sepsi
septic
shock
risk
factor
develop
ard
thrombocytopenia
inconsist
associ
ard
mortal
two
previou
studi
small
patient
seri
repres
noncontemporari
treatment
era
besid
apach
ii
score
thrombocytopenia
risk
factor
ard
mortal
identifi
beij
cohort
associ
replicatedwitha
larger
popul
differ
ethnic
boston
cohort
result
provid
strong
evid
thrombocytopenia
prognost
marker
ard
mortal
beij
boston
cohort
combin
thrombocytopenia
ard
increas
risk
mortal
among
critic
ill
patient
thrombocytopenia
icu
patient
caus
multipl
factor
consid
marker
ill
sever
multipl
organ
dysfunct
score
mod
simplifiedacut
physiolog
score
sap
apach
scoressepsi
alon
caus
moder
thrombocytopenia
maladapt
plateletneutrophil
interactionssignificantli
increas
platelet
activ
aggreg
well
tissu
injuri
lung
epithelium
central
pathogenesi
resolut
ard
intraalveolar
coagul
chang
eg
plateletfibrin
deposit
pulmonari
vascular
thrombi
hallmark
patholog
chang
ard
thu
thrombocytopenia
like
contribut
develop
ard
return
coexist
ard
may
aggrav
thrombocytopenia
increas
mortal
critic
ill
patient
use
platelet
count
criterion
boston
cohort
ml
defin
thrombocytopenia
although
platelet
count
routin
measur
daili
icu
epidemiolog
thrombocytopenia
critic
ill
patient
well
studi
ill
sever
score
system
inconsist
consid
platelet
count
exampl
sofa
score
incorpor
platelet
count
wherea
apach
score
differ
platelet
count
threshold
use
epidemiolog
studi
preval
incid
risk
factor
consequ
thrombocytopenia
among
critic
ill
patient
current
randucla
appropri
methodrecommend
platelet
count
threshold
ml
decreas
platelet
count
epidemiolog
research
thrombocytopenia
take
advantag
larg
patient
popul
boston
cohort
conduct
sensit
analysi
determin
platelet
count
ml
signific
prognost
marker
ard
replic
cutpoint
valu
beij
cohort
differ
beij
boston
cohort
evalu
individu
differ
associ
profil
thrombocytopenia
ard
mortal
patient
least
one
risk
factor
ard
thrombocytopenia
significantli
associ
higher
mortal
beij
cohort
boston
cohort
convers
ardswa
associ
higher
mortal
boston
cohort
beij
cohort
unexpect
ard
increas
mortal
beij
cohort
counterintuit
univari
analysi
thrombocytopenia
would
associ
increas
mortal
ard
group
nonard
group
given
thrombocytopenia
marker
sever
ill
critic
care
popul
gener
howev
raw
number
direct
higher
mortal
lower
platelet
nonard
group
find
could
explain
limit
multipl
subgroup
analysi
rel
small
dataset
moreov
sever
known
risk
factor
comorbid
ard
septic
shock
pneumonia
pancreat
trauma
multipl
transfus
diabet
observ
signific
differ
ard
nonard
patient
beij
cohort
due
rel
scarcityand
high
cost
medic
resourc
gener
chines
popul
particip
hospit
icu
beij
cohortmay
admit
sever
ill
patient
result
less
differ
ill
sever
ard
nonard
patient
accordingli
although
physiolog
variabl
first
hour
icu
admiss
includ
apach
score
compar
ard
nonard
beij
cohort
patient
thrombocytopenia
platelet
count
ml
common
beij
cohort
boston
cohort
vs
respect
also
possibl
differ
ethnic
account
observ
differencesbetween
cohort
base
boston
cohort
studi
protocol
modifi
inclus
sever
pancreat
predispos
condit
ard
sever
pancreat
wellestablish
risk
factor
develop
ard
frequent
observ
critic
ill
patient
china
beij
cohort
identifi
case
sever
pancreat
similar
previou
report
larg
chines
icu
survey
sever
pancreat
case
eventu
develop
ard
icu
admiss
sever
pancreat
associ
ard
risk
associ
lower
mortal
howev
beij
studi
limit
small
sampl
size
patient
enrol
keep
evalu
sever
pancreat
clinic
import
factor
develop
outcom
ard
studi
describ
success
establish
prospect
multicent
cohort
studi
critic
ill
patient
atrisk
ard
beij
china
initi
character
clinic
factor
associ
ard
risk
mortal
reveal
associ
thrombocytopenia
ard
mortal
replic
find
larger
divers
boston
cohort
suggest
beij
cohort
provid
comprehens
data
sampl
identifi
biomark
earli
diagnosi
prognosi
treatment
ard
